Compare Merck & Co., Inc. (MRK) vs Nexgen Energy Ltd. Common Shares (NXE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Nexgen Energy Ltd. Common Shares — how do they compare? Merck & Co., Inc. trades at $146.16 (market cap $351.28B), while Nexgen Energy Ltd. Common Shares trades at $8.89 (market cap $5.80B). The key difference: Merck & Co., Inc. is far larger — about 60.6× Nexgen Energy Ltd. Common Shares's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Nexgen Energy Ltd. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Nexgen Energy Ltd. Common Shares for 1 Days on average.
| MRK | NXE | |
|---|---|---|
Market Cap | $351.28B | $5.80B |
Volume | 7,969,665 | 6,795,738 |
Sector | Health | Energy |
52-Week High | $156.43 | $13.92 |
52-Week Low | $82.49 | $7.56 |
Typical Hold Time | 98 Days | 1 Days |
Enterprise Value | $398.04B | $5.55B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Nexgen Energy Ltd. Common Shares
NexGen Energy develops uranium projects in Canada. Its main asset is the Rook I Project in Saskatchewan, which includes the Arrow uranium deposit.
Read more on NXE →
